Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress
Abstract
Listeria monocytogenes, a Gram-positive facultative anaerobic bacterium, is becoming a popular vector for cancer immunotherapy. Indeed, multiple vaccines have been developed utilizing modified Listeria as a tool for generating immune responses against a variety of cancers. Moreover, over a dozen clinical trials testing Listeria cancer vaccines are currently underway, which will help to understand the utility of Listeria vaccines in cancer immunotherapy. This review aims to summarize current views on how Listeria-based vaccines induce potent antitumor immunity and the current state of Listeria-based cancer vaccines in clinical trials.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 25, 2018
- Source ID
- 10.3390/vaccines6030048
Entities
People
- Adam E. Snook
- John Flickinger Jr.
- Ulrich Rodeck
Organizations
- United States Department of Defense